Yahoo
Saudi - Delayed Quote SAR

Nahdi Medical Company (4164.SR)

89.50 -1.70 (-1.86%)
As of 1:36:46 PM GMT+3. Market Open.
Chart Range Bar
Loading chart for 4164.SR
  • Previous Close 91.20
  • Open 90.20
  • Bid 89.50 x --
  • Ask 89.65 x --
  • Day's Range 89.40 - 91.20
  • 52 Week Range 81.10 - 116.80
  • Volume 88,581
  • Avg. Volume 121,015
  • Market Cap (intraday) 11.635B
  • Beta (5Y Monthly) 0.11
  • PE Ratio (TTM) 14.77
  • EPS (TTM) 6.06
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield 5.20 (5.70%)
  • Ex-Dividend Date Aug 16, 2026
  • 1y Target Est 115.52

Nahdi Medical Company, together with its subsidiaries, engages in the wholesale and retail trading of cosmetics, pharmaceutical, special and healthy foods, and medical equipment products in the Kingdom of Saudi Arabia and the United Arab Emirates. The company also offers mom and baby, beauty, and everyday essentials through retail and online stores. In addition, it operates Nahdi Care polyclinic; and provides virtual care services. Further, the company is involved in operating E-Pharmacist platform; and Nahdi Online, an online pharmacy. Additionally, it provides labor and IT consulting services. Nahdi Medical Company was incorporated in 1986 and is headquartered in Jeddah, the Kingdom of Saudi Arabia.

nahdi.sa

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/1/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

4164.SR
0.37%
MSCI WORLD (^990100-USD-STRD)
9.75%

1-Year Return

4164.SR
18.41%
MSCI WORLD (^990100-USD-STRD)
10.75%

3-Year Return

4164.SR
23.16%
MSCI WORLD (^990100-USD-STRD)
73.81%

5-Year Return

4164.SR
47.04%
MSCI WORLD (^990100-USD-STRD)
52.40%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 2.69B
Earnings --
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B
2B
2B
3B
0.0%
2.0%
4.0%
6.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

100.00
115.52 Average
89.50 Current
142.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.49%

  • Return on Assets (ttm)

    8.53%

  • Return on Equity (ttm)

    30.31%

  • Revenue (ttm)

    10.52B

  • Net Income Avi to Common (ttm)

    788.08M

  • Diluted EPS (ttm)

    6.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    510.65M

  • Total Debt/Equity (mrq)

    69.93%

  • Levered Free Cash Flow (ttm)

    1.21B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: